What happened yesterday tells me that all bets are off with Covid treatments. Between government and FDA, any kind of drug with or without efficacy, with or without a significant safety profile, can be prioritized. Under normal conditions we would have a tremendous advantage due to superiority of Leronlimab. Under current conditions we need faith, patience, and a leadership that will keep pushing the drug forward the best way they can.
Most important take home from last week is clearly the fact that we’re getting more traction. Lets hope this translates into something tangible in the near future. Or that we build on this momentum. I’m concerned that AF will once more disrupt with a BS article